Efficacy of abciximab readministration in coronary intervention

American Journal of Cardiology

Volumn 85, Issue 4, 2000, Pages 435-440

  Madan, Mina ^a   Kereiakes, Dean J ^b   Hermiller, James B ^c   Rund, Michele M ^a   Tudor, Gail ^a   Anderson, Linda ^b   McDonald, Mark B ^b   Berkowitz, Scott D ^a   Sketch Jr , Michael H ^a   Phillips III, Harry R ^a   Tcheng, James E ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b The Carl & Edyth Lindner Center for Research & Education   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; HEPARIN; WARFARIN;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETREATMENT; THROMBOCYTOPENIA; TRANSLUMINAL CORONARY ANGIOPLASTY;

AGED; ANTIBODIES, MONOCLONAL; CORONARY ANGIOGRAPHY; CORONARY DISEASE; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INJECTIONS, INTRAVENOUS; INTRACRANIAL HEMORRHAGES; MALE; MIDDLE AGED; MYOCARDIAL REVASCULARIZATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; POSTOPERATIVE PERIOD; RETROSPECTIVE STUDIES; SAFETY; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 18244420618     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(99)00768-7     Document Type: Article

References (22)

1. Coller B.S., Peerschke E.I., Scudder L.E., Sullivan C.A. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J Clin Invest. 72:1983;325-338.
2. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 330:1994;956-961.
3. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina the CAPTURE study . Lancet. 349:1997;1429-1435.
4. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 336:1997;1689-1696.
5. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet. 352:1998;87-92.
6. Aguirre F.V., Topol E.J., Ferguson J.J., Anderson K., Blankenship J.C., Heuser R.R., Sigmon K., Taylor M., Gottlieb R., Hanovich G., Rosenberg M., Donohue T.J., Weisman H.F., Califf R.M. Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous intervention. Circulation. 91:1995;2882-2890.
7. Lincoff M.A., Tcheng J.E., Califf R.M., Bass T., Popma J.J., Teirstein P.S., Kleiman N.S., Hattel L.J., Anderson H.V., Ferguson J.J., Cabot C.F., Anderson K.M., Berdan L.G., Musco M.H., Weisman H.F., Topol E.J. Standard versus low-dose Weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. Am J Cardiol. 79:1997;286-291.
8. Ferguson J.J., Kereiakes D.J., Adgey A.A.J., Fox K.A.A., Hillegass W.B. Jr, Pfisterer M., Vassanelli C. Safe use of platelet glycoprotein IIb/IIIa inhibitors. Am Heart J. 135:1998;S77-S89.
9. ReoPro (Abciximab) Package Insert. Centocor, and Eli Lilly, and Company. November 1997:4.
10. Mascelli M.A., Lance E.T., Damaraju L., Wagner C.L., Weisman H.F., Jordan R.E. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery GP IIb/IIIa receptor blockade. Circulation. 97:1998;1680-1688.
11. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention IMPACT II . Lancet. 349:1997;1422-1428.
12. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation. 96:1997;1445-1453.
13. Berkowitz S.D., Sane D.C., Sigmon K.N., Shavender J.H., Harrington R.A., Tcheng J.E., Topol E.J., Califf R.M. Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. J Am Coll Cardiol. 32:1998;311-319.
14. Kereiakes D.J., Essell J.H., Abbottsmith C.W., Broderick T.M., Runyon J.P. Abciximab associated profound thrombocytopenia therapy with immunoglobulin and platelet transfusion . Am J Cardiol. 78:1996;1161-1163.
15. Berkowitz S.D., Harrington R.A., Rund M.M., Tcheng J.E. Acute profound thrombocytopenia after c7E3 Fab (Abciximab) therapy. Circulation. 95:1997;809-813.
16. Berkowitz S.D., Harrington R.A., Rund M.M., Tcheng J.E. Acute profound thrombocytopenia after c7E3 Fab (Abciximab) therapy. (lett) Circulation. 96:1997;3809.
17. Bednar B., Bednar R.A., Cook J.J., Bollag D.M., Chang C.T., Stanley L.G., McQueney P.A., Egberton M.S., Hartman G.D., Holahan M.A., Lynch J.J., Gould R.J. Drug-dependent antibodies against GP IIb/IIIa induce thrombocytopenia. (abstr) Circulation. (suppl I):1996;I99.
18. Alexander J.H., Greenbaum A.B., Hudson M.P., Kong D.F., Miller J.M., Tung C.Y. Session highlights from the American College of Cardiology scientific sessions March 29 to April 1, 1998 . Am Heart J. 135:1998;1099-1114.
19. Curtis B.R., McFarland J.G., Garrity M.M., Aster R.H. Thrombocytopenia induced by abciximab studies of pathogenesis (abstr) . Blood. 92:1998;181a.
20. Tcheng J.E., Ellis S.G., George B.S., Kereiakes D.J., Kleiman N.S., Talley J.D., Wang A.L., Weisman H.F., Califf R.M., Topol E.J. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation. 90:1994;1757-1764.
21. Tcheng J.E. Glycoprotein IIb/IIIa receptor inhibitors putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective . Am J Cardiol. 78:1996;35-40.
22. Mehta C.R., Patel N.R. Exact logistic regression theory and examples . Statist Med. 14:1995;2143-2160.